https://www.ncbi.nlm.nih.gov/pubmed/30575878
JAMA Slomski A
Dec 21st, 2018 - Chemoimmunotherapy for Triple-Negative Breast Cancer.|2018|Slomski A,|
https://www.ncbi.nlm.nih.gov/pubmed/30573511
Haematologica Qualls D, Abramson JS
Dec 20th, 2018 - Central nervous sytem recurrence of diffuse large B-cell lymphoma is an uncommon but devastating event, making identification of patients at high risk for relapse within the central nervous system essential for clinicians. Modern risk stratification includes both clinical and biologic features. A validated clinical risk model employing the 5 traditional international prognostic index risk facto...
https://www.ncbi.nlm.nih.gov/pubmed/30530733
Cancer Discovery;
Dec 12th, 2018 - Ibrutinib should be a standard of care for many patients with chronic lymphocytic leukemia, according to results from two phase III trials. The BTK inhibitor, given alone or in combination with rituximab, improved clinical outcomes-including progression-free survival-when compared with chemoimmunotherapy regimens.
https://www.ncbi.nlm.nih.gov/pubmed/30535947
Current Hematologic Malignancy Reports; Khan M, Siddiqi T
Dec 12th, 2018 - While chemoimmunotherapy has improved outcomes in chronic lymphocytic leukemia (CLL), it is not curative, has significant relapse rates, and is not always well tolerated. Recently, novel targeted therapies have been developed to increase response rates and reduce toxicity, especially in high-risk disease. Current goals of CLL therapies are to produce deep and durable, especially minimal ...
https://www.ncbi.nlm.nih.gov/pubmed/30527922
European Journal of Internal Medicine; Eichhorst B, Hallek M et. al.
Dec 12th, 2018 - Chronic lymphocytic leukemia (CLL) is a disease characterized by an increasing incidence with age reaching 35/100,000 in patients over 85 years. Elderly CLL patients carry several challenges, which have to be considered particularly in advanced stages including a higher risk of infections and individual differences in comorbidities and geriatric syndromes. Although no specific tool for geriatri...
https://www.mdedge.com/hematologynews/nhlhub/article/190863/cll/ibrutinib-rituximab-new-standard-care-younger-cll-patients
Neil Osterweil
Dec 11th, 2018 - SAN DIEGO – The combination of ibrutinib and rituximab was associated with a two-thirds reduction in chronic lymphocytic leukemia (CLL) progression, compared with standard chemoimmunotherapy in patients younger than 70 years old, interim results of a phase 3 randomized trial showed. Among 529 patients with previously untreated, symptomatic CLL randomly assigned to ibrutinib-rituximab (IR.
https://www.ncbi.nlm.nih.gov/pubmed/30504294
Hematology. American Society of Hematology. Education Program; Cohen JB
Dec 7th, 2018 - Most patients with aggressive non-Hodgkin lymphoma will be cured with initial chemoimmunotherapy; however, most patients with relapsed disease will not be cured and will die as a result of their disease. In these cases, continued treatment with conventional chemotherapy is typically not of benefit and can contribute to significant toxicities and decreased quality of life for patients. Fo...
https://www.ncbi.nlm.nih.gov/pubmed/30504308
Hematology. American Society of Hematology. Education Program; Leonard JP, Nastoupil LJ et. al.
Dec 7th, 2018 - The initial approach to the management of follicular lymphoma (FL) is challenging for patients and physicians. Most FL patients present with minimal symptoms; given the lack of a survival benefit to early treatment in this population, a period of observation without therapy is often appropriate. Once there is disease progression beyond low-tumor-burden criteria or symptoms prompting interventio...
https://www.ncbi.nlm.nih.gov/pubmed/30504317
Hematology. American Society of Hematology. Education Program; Jain N
Dec 7th, 2018 - The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically in the last few years. The role of chemoimmunotherapy has declined significantly for patients with CLL. Fludarabine, cyclophosphamide, rituximab chemotherapy remains the standard frontline therapy for young fit patients with CLL, especially if IGHV mutated. For older adults, ibrutinib has been shown to...
https://www.ncbi.nlm.nih.gov/pubmed/30504318
Hematology. American Society of Hematology. Education Program; Brown JR
Dec 7th, 2018 - Although the therapy of chronic lymphocytic leukemia (CLL) has changed rapidly over the last 5 years, the key considerations in selecting a therapy for a previously treated patient with CLL continue to include the nature of the prior therapy and the duration of prior remission to that therapy, the prognostic features of the disease, and the health and comorbidities of the patient in question. F...
https://www.ncbi.nlm.nih.gov/pubmed/30501481
The New England Journal of Medicine; Woyach JA, Ruppert AS et. al.
Dec 7th, 2018 - Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not been compared with chemoimmunotherapy. We conducted a phase 3 trial to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab, relative to chemoimmunotherapy. Patients 65 years of age or ol...
https://www.mdedge.com/fedprac/avaho/article/190538/leukemia-myelodysplasia-transplantation/older-cll-patients-see-better
Dec 6th, 2018 - SAN DIEGO – In the phase 3 Alliance A041202 trial of older patients with previously untreated chronic lymphocytic leukemia (CLL), ibrutinib showed superior progression-free survival (PFS). Results of the trial were reported by Jennifer A.
https://www.ashclinicalnews.org/on-location/older-patients-cll-ibrutinib-beats-standard-chemoimmunotherapy/
Dec 4th, 2018 - Results from a randomized phase III study indicate that the Bruton tyrosine kinase (BTK) inhibitor ibrutinib was superior to standard-of-care chemoimmunotherapy for older patients with chronic lymphocytic leukemia (CLL). Lead author Jennifer A. Woyach, MD, from The Ohio State University Comprehensive Cancer Center in Columbus, presented the findings of the Alliance North American Intergr...
https://www.ncbi.nlm.nih.gov/pubmed/30523716
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology;Ennishi D, Jiang A et. al.
Dec 3rd, 2018 - High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to understand the biologic underpinnings of HGBL-DH/TH with BCL2 rearrangements (HGBL-DH/TH- BCL2) and diffuse large B-cell lymphoma (DLBCL) morphology through examination of gene expression. We analyzed RNA sequencing data from 157 de novo ...
https://www.medscape.com/viewarticle/905623
Nov 30th, 2018 - The guidelines on the diagnosis, treatment, and follow-up of Waldenstrom macroglobulinemia were released on October 1, 2018, by the European Society for Medical Oncology (ESMO).[1] Diagnosis Waldenstrom macroglobulinemia (WM) is diagnosed based on histopathologic confirmation of bone marrow (BM) infiltration by monoclonal lymphoplasmacytic cells and serum monoclonal immunoglobulin M (IgM), conf...
https://www.medpagetoday.com/hematologyoncology/lymphoma/76531
Nov 26th, 2018 - More than a third of patients with symptomatic indolent lymphoma required no chemotherapy during more than 10 years of follow-up after initial treatment with rituximab (Rituxan), data from two randomized Scandinavian studies showed. Three-fourths of the patients remained alive at the end of follow-up, including 38% of patients with follicular lymphoma never treated with chemotherapy. The random...
https://www.ncbi.nlm.nih.gov/pubmed/30464679
Current Oncology (Toronto, Ont.); Stewart DA, Boudreault JS et. al.
Nov 23rd, 2018 - Non-Hodgkin lymphoma (nhl) is the most common hematologic malignancy. Diffuse large B-cell lymphoma (dlbcl) and follicular lymphoma (fl) constitute 55% of new nhl cases and are initially treated with rituximab-based chemoimmunotherapy. Relative to intravenous (IV) rituximab, a subcutaneous (sc) formulation approved in 2016 has comparable pharmacokinetics, efficacy, and safety, and a grea...
https://www.medscape.com/viewarticle/905521
Nov 23rd, 2018 - The premier event in hematology is celebrating its diamond anniversary. This will be the 60th annual meeting of the American Society of Hematology (ASH). It will be returning to the city of San Diego, California, and will run from November 30 to December 4. More than 25,000 attendees from 155 countries are expected, and more than 4800 abstracts will be presented, Aaron Gerds, MD, chair of ASH's...
https://www.mdedge.com/jcomjournal/article/189383/aggressive-lymphomas/ash-2018-coming-attractions-look-big-picture/page/0/1
Nov 21st, 2018 - Among these star attractions are results of a phase 3, randomized study of daratumumab (Darzalex) plus lenalidomide and dexamethasone versus lenalidomide-dexamethasone alone for patients with newly diagnosed multiple myeloma who are ineligible for transplant. The investigators found that adding daratumumab reduced the risk of disease progression or death by close to 50%, supporting the combinat.
https://www.ncbi.nlm.nih.gov/pubmed/30460980
British Journal of Haematology; Al-Sawaf O, Bahlo J et. al.
Nov 21st, 2018 - Clinical management of chronic lymphocytic leukaemia (CLL) in patients aged ≥80 years is based on limited evidence due to the lack of published information. Therefore, we analysed CLL patients aged ≥80 years using data from seven phase III clinical trials of the German CLL Study Group. Among 3552 participants, 152 were ≥80 years old at initiation of first-line study treatment. Median age was 82...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.